Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 1
1(20.0%)
Phase 2
1(20.0%)
Phase 4
1(20.0%)
5Total
Phase 3(2)
Phase 1(1)
Phase 2(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06411925Phase 4Recruiting

The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients

Role: lead

NCT03827590Phase 3Unknown

Clinical Trials to Assess the Efficacy and Safety of HLIM

Role: lead

NCT03826485Phase 1Unknown

Safety, Pharmacokinetic Study of PRIC in Healthy Adult Subjects

Role: lead

NCT01740986Phase 2Completed

Safety and Efficacy of SA09012 in Asthma

Role: lead

NCT01539304Phase 3Completed

Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis

Role: lead

All 5 trials loaded